Search clinical trials for: FTIH

Total 51 results

GlaxoSmithKline

Not yet recruiting

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

Systemic Lupus Erythematosus

United Kingdom
Eccogene

Recruiting

FTIH of ECC5004 in Healthy and Diabetic Participants

Type 2 Diabetes Mellitus

United States
Eccogene

Recruiting

FTIH of ECC4703 in Healthy Volunteers

Non-alcoholic Steatohepatitis (NASH)

United States
Eccanga Pty Ltd
Syneos Health

Recruiting

FTIH Study of ECC0509 in Healthy Volunteers

Osteoarthritis | Nonalcoholic Steatohepatitis

Australia
GlaxoSmithKline

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants

Tuberculosis

United Kingdom, Netherlands
GlaxoSmithKline

Active, not recruiting

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Neoplasms

Spain, Netherlands, United States, Japan, France, Australia, Korea, Republic of, Canada
GlaxoSmithKline

Withdrawn

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants

Colitis, Ulcerative

United Kingdom
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Completed

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

HIV Infections

United States
GlaxoSmithKline

Terminated

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

Heart Failure

United Kingdom
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

HIV Infections

United States
GlaxoSmithKline
Wellcome Trust; Department of Health and Human Services

Completed

Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.

Urinary Tract Infections

United Kingdom
GlaxoSmithKline

Terminated

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Neoplasms

United States, Spain, Canada, Australia
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
GlaxoSmithKline

Completed

Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

Hypertension

South Africa
GlaxoSmithKline

Completed

First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

Asthma

United Kingdom, Germany
GlaxoSmithKline

Terminated

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

Arthritis, Rheumatoid

United Kingdom
GlaxoSmithKline
Parexel

Terminated

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Neoplasms, Pancreatic

United States
GlaxoSmithKline

Completed

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

Muscular Dystrophies

United States
ViiV Healthcare

Completed

A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

HIV Infections

United Kingdom
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects

Tuberculosis

United Kingdom
GlaxoSmithKline

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects

Bronchiectasis

United Kingdom
GlaxoSmithKline

Completed

A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects

Hepatitis C, Chronic

Australia
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

Cachexia

United States
GlaxoSmithKline

Terminated

NOGO-A in Multiple Sclerosis FTIH

Multiple Sclerosis

Australia
GlaxoSmithKline

Completed

Effect of GSK1160724 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

First Time in Human Study With GSK1018921

Schizophrenia

Germany
GlaxoSmithKline

Completed

FTIH Study With GSK958108

Premature Ejaculation

United Kingdom
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
GlaxoSmithKline

Completed

GSK2239633 FTIH Study

Asthma

Netherlands
GlaxoSmithKline

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects

Diabetes Mellitus, Type 2

United States
GlaxoSmithKline

Completed

First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

Schizophrenia

United Kingdom
GlaxoSmithKline

Completed

FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers

Gastroparesis

Australia
GlaxoSmithKline

Completed

A First-Time-In-Human Study in Healthy Subjects (FTIH)

Obesity

United Kingdom
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia
GlaxoSmithKline

Completed

The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects (FTIH)

Cough

United Kingdom
GlaxoSmithKline

Completed

Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers (FTIH)

Cancer

Australia
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
GlaxoSmithKline

Completed

GSK2018682 FTIH in Healthy Volunteers (P1A114070)

Multiple Sclerosis

Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

Cachexia

United States
GlaxoSmithKline

Completed

Dose-Escalation Study of GSK2126458 (FTIH)

Solid Tumours

United States, Netherlands
GlaxoSmithKline

Completed

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline
Clinical Unit at Cambridge (Addenbrooks)

Completed

A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects

Inflammatory Bowel Diseases

United Kingdom
GlaxoSmithKline

Completed

First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients

Idiopathic Pulmonary Fibrosis

United Kingdom
GlaxoSmithKline

Completed

Effect of GSK704838 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Flatley Discovery Lab LLC

Completed

FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

Cystic Fibrosis

United Kingdom
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
GlaxoSmithKline

Terminated

Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

Hepatitis C | Hepatitis C, Chronic

United States

3

Subscribe